Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
10:30:00 08/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 5,816.00 JPY | +0.87% |
|
+0.62% | +20.29% |
| 10-07 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
| 10-07 | Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading | MT |
| Market Cap | 9,207B 58.21B 52.01B 48.53B 44.08B 83.02B 5,631B 83.64B 583B 228B 2,864B 219B 214B | P/E 2027 * |
45.7x | P/E 2028 * | 29x |
|---|---|---|---|---|---|
| Enterprise Value | 13,113B 82.92B 74.09B 69.12B 62.78B 118B 8,021B 119B 831B 324B 4,079B 311B 305B | EV / Sales 2027 * |
2.79x | EV / Sales 2028 * | 2.7x |
| Free-Float |
99.25% | Yield 2027 * |
3.54% | Yield 2028 * | 3.61% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
Deutsche Boerse AG
| TKD | Delayed | |
|
OTC Markets
| TKPHF | Delayed | |
|
Tradegate
| TKD | Real-time | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.87% | ||
| 1 week | +0.62% | ||
| Current month | +0.62% | ||
| 1 month | +0.68% | ||
| 3 months | +6.75% | ||
| 6 months | +0.31% | ||
| Current year | +20.29% |
| 1 week | 5,606 |  | 5,870 |
| 1 month | 5,557 | | 6,030 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/09/26 | Sell | Executive/Senior Manager | -34,535 | 0.0022% | ||
| 02/09/26 | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 19/08/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.87% | +0.62% | +33.36% | +27.04% | 58.21B | |
| +2.70% | +2.73% | +40.91% | +110.31% | 1,060B | |
| +1.44% | -2.38% | +36.83% | +63.95% | 623B | |
| +1.75% | +3.73% | +16.55% | +83.05% | 480B | |
| +0.60% | -1.73% | +62.98% | +37.46% | 352B | |
| -1.72% | +3.12% | +24.78% | +45.10% | 345B | |
| -1.05% | +0.05% | +14.13% | +35.80% | 274B | |
| -1.04% | -0.81% | -4.69% | +12.20% | 249B | |
| +2.60% | -2.00% | +39.77% | +54.44% | 223B | |
| +1.82% | -1.48% | +25.75% | +96.48% | 182B | |
| Average | +0.29% | -0.46% | +29.04% | +56.58% | 384.62B | |
| Weighted average by Cap. | -0.05% | +0.03% | +32.02% | +70.05% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,701B 29.72B 26.56B 24.78B 22.51B 42.39B 2,875B 42.7B 298B 116B 1,462B 112B 109B | 4,788B 30.27B 27.05B 25.24B 22.92B 43.17B 2,929B 43.5B 303B 118B 1,489B 114B 111B |
| Net income | 196B 1.24B 1.11B 1.04B 941M 1.77B 120B 1.79B 12.45B 4.86B 61.12B 4.66B 4.56B | 323B 2.04B 1.82B 1.7B 1.55B 2.91B 197B 2.93B 20.44B 7.99B 100B 7.66B 7.5B |
| Net Debt | 3,907B 24.7B 22.07B 20.59B 18.7B 35.22B 2,389B 35.49B 247B 96.67B 1,215B 92.73B 90.73B | 3,702B 23.41B 20.92B 19.51B 17.72B 33.38B 2,264B 33.63B 234B 91.61B 1,152B 87.88B 85.98B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/10/26 | ¥5,816.00 | +0.87% | 4,535,300 |
| 07/10/26 | ¥5,766.00 | +0.82% | 3,222,600 |
| 06/10/26 | ¥5,719.00 | +1.42% | 3,536,400 |
| 05/10/26 | ¥5,639.00 | -0.07% | 3,269,900 |
| 02/10/26 | ¥5,643.00 | -1.54% | 4,217,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
